08 August 2018
Visiongain has launched a new pharma report Latin American Pharmaceutical Market Outlook 2018-2028: Brazil, Mexico, Venezuela, Argentina, Colombia, Chile, Rest of Latin America, Generics, OTC, Biosimilars, Originator Drugs
The Latin American pharmaceutical market accounts for 8% of the global pharmaceutical industry, and is one of its fastest growing markets. Macroeconomic conditions are hampering growth in the short term, but long-term growth is expected at high rates to 2028 and beyond. Many multinational companies have successfully gained entry to this market and are making large gains, but it remains a challenging environment for new entrants. The Latin American market requires strong local knowledge, as there are large differences between its constituent nations.
The lead analyst of this report said “The Latin American pharmaceutical market will continue to grow at a much higher rate than other, more mature markets for the next ten years. The reasons behind this growth will shift from expanding coverage to increasing incidence of diseases as the nations of Latin America develop economically. Governments across the region are looking to increase access to health care and an ageing population coupled with rises in the incidence of chronic diseases are driving demand.
Competition is high from both foreign and domestic companies, and national regulations can make investment difficult. Nevertheless, success in the Latin American pharmaceutical market is crucial for pharmaceutical companies seeking to maintain growth rates as developed markets stagnate.”
Leading companies featured in the report include Pfizer Inc., Bayer AG, Sanofi S.A, Novartis AG
And EMS SA.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.
30 November 2020
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.